Study design (if review, criteria of inclusion for studies)
Controlled: No.1 Randomised: No.2 Open: Yes.3 Single blind: No.4 Double blind: No.5 Parallel group: No.6 Cross over: No
Participants
Principal inclusion criteria: 1.Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF), and, when appropriate, an assent form.
Interventions
Main objective of the trial: To evaluate the effects of ELX/TEZ/IVA on cough and physical activity using wearable technology
Outcome measures
Primary end point(s): Percent reduction from baseline in cough frequency (cough events per day) to the average of Week 8 through Week 12